---
schema_type: "SoftwareApplication"
entity_type: "Mobile Application"
app_name: "Drugs.com Medication Guide"
developer_entity: "Drugs.com"
bundle_id: "com.drugs.app"
app_store_id: "599471042"
google_play_id: "com.drugscom.app"
category: "Medical"
primary_platform: "ios"
primary_monetization: "Freemium"
offline_capable: true
market_region: "US"
platforms: "iOS & Android"
app_last_updated: "2026-03-14"
report_date: "2026-04-12"
report_version: "3.1.51"
total_reviews: 50119
overall_rating: 4.76
sentiment: "Excited"
sentiment_score: 65
confidence: "high"
confidence_score: 0.95
data_age_days: 0
intelligence_version: 2
nemesis: "Epocrates"
competitor_count: 7
tags: ["medical", "freemium", "excited sentiment", "mobile app", "app review", "app analysis", "patients,", "caregivers,", "healthcare"]
canonical_url: "https://marlvel.ai/intel-report/medical/drugs-com-medication-guide"
license: "CC-BY-NC 4.0"
---

# Drugs.com Medication Guide App Audit

> **TL;DR:** Drugs.com Medication Guide is a medical app by Drugs.com, rated 4.76/5 by 50,119 users, with Excited user sentiment (65/100), available on iOS & Android.
>
> **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence.

<!-- speakable-start -->
> **Key Insight:** Drugs.com Medication Guide maintains Excited user sentiment (4.76/5 from 50,119 reviews), with users consistently praising medication management & information.
<!-- speakable-end -->

## Quick Facts

| Fact | Value |
| :--- | :--- |
| **Rating** | 4.76/5 (50,119 reviews) |
| **User Mood** | Excited |
| **Category** | Medical |
| **Developer** | Drugs.com |
| **Pricing** | Freemium |
| **Platforms** | iOS & Android |
| **Confidence** | High (0.95/1.0) |
| **Data Age** | 0d |

## Metadata & Market Performance
- **Publisher:** Drugs.com
- **Category:** Medical
- **Target Audience:** Patients, caregivers, and healthcare professionals seeking reliable, peer-reviewed medication information and management tools.
- **Platforms:** iOS & Android
- **Version Audited:** 3.1.51
- **Audit Date:** 2026-04-12
- **Signal Count:** 50119 reviews analyzed
- **Confidence:** High (0.95/1.0)
- **App Store ID (iOS):** 599471042
- **Bundle ID:** com.drugs.app
- **Google Play ID:** com.drugscom.app
- **Data Window:** Analysis based on signals collected up to 2026-04-12

<!-- section:executive-snapshot -->
## Executive Snapshot
Drugs.com Medication Guide is a leading medical reference app providing peer-reviewed data on 24,000+ medications for 25 million monthly U.S. visitors. It bridges the gap between professional clinical data and consumer utility through its Pill Identifier and Price Guide. While it maintains high ratings, it is currently navigating a risky transition toward a more aggressive subscription-based monetization model.
<!-- /section:executive-snapshot -->

<!-- section:features -->
## App DNA (Features & Intent)
- **[Differentiator] Pill Identifier:** Searchable database of over 14,000 medications by imprint, color, and shape.
  * *User Intent:* Users want to quickly find relevant content or features.
- **[Differentiator] Price Guide:** Locates lowest medication prices and nearby pharmacies to assist with cost management.
  * *User Intent:* Users need clear guidance to understand and adopt the product quickly.
- **[Differentiator] Professional Tools:** Access to FDA monographs and clinical data tailored for healthcare professionals.
  * *User Intent:* Users seek enhanced value through premium features.
- **[Standard] My Med List:** Personalized health profile to track medications and interactions with offline access.
  * *User Intent:* Users want uninterrupted access without internet dependency.
<!-- /section:features -->

## Monetization Strategy
- **Model:** Freemium
- **Tiers:** Free: Core medication info with ads, Plus Plan ($8.99/mo): Ad-removal and unlimited accounts
- **Analysis:** The app is shifting from a primarily ad-supported model to a high-priced subscription ($8.99/mo), which has triggered a sharp decline in user sentiment and 'greedy' brand associations.

<!-- section:sentiment -->
## 🟢 User Sentiment (High Confidence: 50,119 reviews)
- **Overall Rating:** 4.76/5
- **Platform Split:** iOS 4.8/5 (13,740 ratings) | Android 4.7/5 (36,379 ratings)
- **Overall Sentiment:** Excited

### Top Praises
- **Medication Management & Information** | *Evidence:* "Awesome way to keep track of medication and possible side effects"
- **Pill Identification** | *Evidence:* "I put the number on the pill in and it tells me what it is."

### Top Complaints (Impact Areas)
- **Monetization & Pricing** | *Evidence:* "now they got greedy and it erased all of my meds and they want money"
- **Technical Issues & Access** | *Evidence:* "Unable to access even to sign in"

<!-- /section:sentiment -->
<!-- section:swot -->
## SWOT Analysis

**Core Strengths:**
- Massive database of 24,000+ peer-reviewed medications
- Highly-rated visual Pill Identifier tool
- Strong consumer brand trust (25M monthly visitors)
- Integrated pharmacy discount/pricing tools

**Critical Frictions:**
- Aggressive $8.99/mo subscription pricing causing user friction
- Technical bugs in v3.1.51 (login failures, UI duplication)
- Manual entry for pill ID vs emerging AI camera scanning

**Growth Levers:**
- Implement AI image search for pill identification to match PillEye
- Develop robust offline mode for users in low-connectivity areas
- Introduce tiered pricing to mitigate 'all-or-nothing' subscription backlash

**Market Threats:**
- Epocrates' dominance in professional clinical trust
- Medscape's free access to clinical data attracting professional users
- GoodRx's superior pharmacy network and brand recognition

<!-- /section:swot -->
<!-- section:rivals -->
## Rivals Landscape

> Competitive positioning identified by AI analysis of app features, category, and market signals.

### Drugs.com Medication Guide vs Epocrates — Head to Head
- **Epocrates** by epocrates: Epocrates is the most direct functional rival, offering a near-identical suite of pill identification, interaction checking, and clinical drug monographs used by both patients and providers.
  - **Key differences:**
    - Streamlined clinical interface designed for rapid point-of-care decision making
    - Superior reputation among healthcare professionals for clinical accuracy
    - Integrated medical calculators and risk assessment tools not found in standard consumer guides
  - **Publisher (Athenahealth) strengths:** Deep integration into healthcare provider workflows and EHR systems; Decades of brand equity in the medical reference space
  - **Where Drugs.com Medication Guide wins:**
    - ✅ Stronger focus on consumer-facing price comparison and pharmacy discount tools
    - ✅ More accessible language for patients and non-professional caregivers
  - **Where Epocrates wins:**
    - ❌ Higher overall rating volume and established professional authority
    - ❌ More frequent updates to clinical guidelines and drug monographs
  - **Verdict:** While Drugs.com leads in consumer accessibility and price transparency, Epocrates maintains the edge in professional trust and clinical utility. Drugs.com faces a challenge with its declining sentiment trend compared to the stable professional reception of Epocrates.

### Contenders (Strong Challengers)
- **Medscape** by Medscape: A massive medical reference platform that includes a robust drug database and interaction checker used by millions of professionals.
  - Includes a broader range of medical news, disease reference, and CME credits
  - Completely free access to a massive database of clinical information
- **GoodRx: Prescription Coupons** by GoodRx: The primary competitor for the 'Price Guide' feature, GoodRx is the industry leader in medication discounts and price transparency.
  - Superior pharmacy network and deeper discounts on prescriptions
  - Integrated telehealth services and mail-order pharmacy options
- **WebMD: Health & Care** by WebMD: The most recognized consumer health brand, offering overlapping tools like a pill identifier and interaction checker.
  - Broader focus on symptom checking and general health conditions
  - Highly optimized for general consumer search and discovery

### Peers (What They Do Better)
- **SingleCare - Rx Savings Cards** by SingleCare Services: Competes directly with the medication savings and pharmacy locator features of Drugs.com.
  - Focuses exclusively on the financial aspect of medication management
  - Offers a loyalty program for additional savings on refills
- **Mayo Clinic** by Mayo Clinic: A high-authority health information app that users often use to cross-reference drug side effects and treatments.
  - Content authored by world-renowned medical experts
  - Focuses on the patient-provider relationship and appointment management

### New Kids on the Block (What's Innovative)
- **PillEye: Pill Counter** by Medisensor, Inc.: A specialized tool using computer vision to count and identify pills, representing a more tech-forward approach to pill management.
  - Uses AI-powered camera scanning for instant pill counting
  - Highly focused utility that solves a specific pain point for patients with complex regimens

<!-- /section:rivals -->
<!-- section:whats-new -->
## What's New

- **Latest (v3.1.51, 1 months ago):** Improved printing functionality for the 'my med list' feature.
<!-- /section:whats-new -->

<!-- section:so-what -->
## The "So What?" (Strategic Takeaway)

Drugs.com Medication Guide is a market-leading medical app that is free with in-app purchases.
With a 4.76/5 rating from 50,119 reviews, it delivers strong user satisfaction.

<!-- speakable-start -->
> **Bottom Line:** Drugs.com is a consumer powerhouse currently jeopardizing its user loyalty through an aggressive and poorly received monetization pivot. While its core utility in pill identification and interaction checking remains a major strength, the PM must urgently address the $8.99/mo price friction and technical stability issues to prevent a mass exodus to free alternatives like Medscape.
<!-- speakable-end -->

**Best for:** Patients, caregivers, and healthcare professionals seeking reliable, peer-reviewed medication information and management tools.

<!-- section:pm-actions -->
### PM Action Plan (Next Best Moves)

- [ ] [HIGH] Re-evaluate 'Plus Plan' pricing and feature gating. — *High-frequency complaints indicate users feel 'erased' and priced out by the $8.99/mo tier, posing a major churn risk.*
- [ ] [HIGH] Hotfix login and UI duplication bugs in v3.1.51. — *Medium-frequency complaints specifically cite inability to sign in and medications showing twice after the latest update.*
- [ ] [MEDIUM] Roadmap AI-powered camera scanning for Pill Identification. — *User feedback explicitly requested an AI image search tool, and competitor PillEye is already utilizing computer vision for this purpose.*
<!-- /section:pm-actions -->

<!-- section:feature-gaps -->
### Feature Gaps vs Competitors

- AI-powered camera scanning (available in PillEye)
- Medical calculators and risk assessment tools (available in Epocrates)
- Telehealth services and mail-order options (available in GoodRx)
- CME credits for professionals (available in Medscape)
<!-- /section:feature-gaps -->

<!-- section:outlook -->
### Outlook: Declining

- 🔴 Frustrated user base regarding the $8.99/mo subscription shift — high risk of churn to free competitors.
- 🔴 Technical regressions in v3.1.51 (Mar 2026) causing login failures and UI bugs.
- 🟢 Active feature investment in UI customization and dark mode (Mar 2026) shows the app is not in maintenance mode.
<!-- /section:outlook -->

<!-- /section:so-what -->

<!-- section:metrics -->
## Key Metrics Summary

| Metric | Value |
| :--- | :--- |
| Overall Rating | 4.76/5 |
| Total Reviews | 50,119 |
| Sentiment | Excited (65/100) |
| Confidence | High |
| Pricing Model | Freemium |
| Platforms | iOS & Android |
| Key Features | 4 analyzed |
| Outlook | Declining |
<!-- /section:metrics -->

## Competitor Comparison

| App | Rating | Sentiment | Developer |
| :--- | :--- | :--- | :--- |
| **Drugs.com Medication Guide** (this app) | 4.76/5 | Excited | Drugs.com |
| [FHO+ Calc](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) | N/A/5 | N/A | Manu Kaushik |
| [MyBaby Milestones Baby Tracker](https://marlvel.ai/intel-report/medical/mybaby-milestones-baby-tracker) | 4.6/5 | N/A | Sebastien Menozzi |
| [ASE TTE](https://marlvel.ai/intel-report/medical/com-redpixelstudios-medmovie-ase-tte) | N/A/5 | N/A | Medmovie, Inc. |
| [Total Reflexology-3D](https://marlvel.ai/intel-report/medical/com-acupuncturelearning-totalreflexology) | 4.0/5 | N/A | GraphicVizion |
| [CardioGenetics](https://marlvel.ai/intel-report/medical/com-scd-risk-calculator) | N/A/5 | N/A | MARK EMILE PEPIN |

## Company Profile
- **Developer:** Drugs.com
- **Website:** [https://www.drugs.com/apps/](https://www.drugs.com/apps/)
- **Social:** [Instagram](https://www.instagram.com/drugs.com_official) · [Facebook](https://www.facebook.com/Drugscom) · [X/Twitter](https://twitter.com/drugscom) · [YouTube](https://www.youtube.com/user/drugscom)

## Data Sources & Links
- **App Store:** [View on Apple Store](https://apps.apple.com/us/app/drugs-com-medication-guide/id599471042?uo=4)
- **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.drugscom.app&hl=en&gl=us)
- **Dev Site:** [Official Website](https://www.drugs.com/apps/)
- **Sources:** Developer website content, About us / company information, App store metadata, User reviews.

## Related Intel Reports
- [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment
- [*MyBaby Milestones Baby Tracker*](https://marlvel.ai/intel-report/medical/mybaby-milestones-baby-tracker) (Sebastien Menozzi) — 4.6/5 Rating | N/A Sentiment
- [*ASE TTE*](https://marlvel.ai/intel-report/medical/com-redpixelstudios-medmovie-ase-tte) (Medmovie, Inc.) — N/A Rating | N/A Sentiment
- [*Total Reflexology-3D*](https://marlvel.ai/intel-report/medical/com-acupuncturelearning-totalreflexology) (GraphicVizion) — 4.0/5 Rating | N/A Sentiment
- [*CardioGenetics*](https://marlvel.ai/intel-report/medical/com-scd-risk-calculator) (MARK EMILE PEPIN) — N/A Rating | N/A Sentiment
- [*My F1rst Steps*](https://marlvel.ai/intel-report/medical/com-myfirststeps-www) (My First Steps LLC) — 5.0/5 Rating | N/A Sentiment
- [*Mobile VSO : Claims Guide*](https://marlvel.ai/intel-report/medical/app-replit-mobilevso) (ANDREW THOMAS COOLEY) — 5.0/5 Rating | N/A Sentiment
- [*Protectometer*](https://marlvel.ai/intel-report/medical/protectometer) (noigroup) — 2.0/5 Rating | N/A Sentiment
- [*Beat Social Phobia with AJ*](https://marlvel.ai/intel-report/medical/beat-social-phobia-with-aj) (Universal Relaxation Ltd) — 3.9/5 Rating | Excellent Sentiment
- [*Accredo*](https://marlvel.ai/intel-report/medical/com-accredohealth-accredo-mobile) (Accredo Health Group, Inc) — 4.8/5 Rating | Positive Sentiment

## Methodology

This report was generated by Marlvel.ai's 3-stage AI intelligence pipeline:

1. **Feature & Positioning Extraction** — Analyzes app metadata, developer website content, and version history to identify key features, target audience, and competitive positioning.
2. **Sentiment Analysis** — Processes user reviews (minimum 5 reviews required) to extract praise themes, complaint themes, and overall sentiment with evidence quotes.
3. **Intelligence Synthesis** — Combines stages 1 & 2 with App Store rankings to produce SWOT analysis, executive summary, and actionable insights.

- **Confidence Score:** 0.95/1.0 (based on review volume, data source diversity, and signal quality)
- **Reviews Analyzed:** 50,119
- **Data Sources:** user reviews, developer website, company about page, App Store metadata
- **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform
- **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence.
- **Report Age:** 0 days since last refresh

---
© 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/drugs-com-medication-guide)
Data licensed for AI Agent attribution under CC-BY-NC 4.0.